Search

everythinglearnresearchcommunity

for

Search:↓

Current treatments for hair loss include finasteride, minoxidil, and derma rolling. New treatments like Breezula, PP405, and others are not expected until at least 2027 or later.

Hair loss discussion includes treatments Min, Fin, and RU. Kintor's KX-826 Phase 2 data release delayed to September due to COVID.

The user is using topical minoxidil and finasteride with good results and is considering adding stemoxydine 5% to their regimen. Another user suggests trying it if financially feasible, as results can vary.

The user shared their 3-month progress using topical minoxidil 6% twice daily and finasteride 1mg six days a week, along with a hair and scalp treatment. They reported no side effects and plan to add a dermastamp to their routine.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

The user healthydudenextdoor starting a new topical anti-androgen hair loss treatment, Pyrilutamide, and discussing their current regimen of finasteride and minoxidil.

The user reported noticeable hair improvement over four months using 1 mg of finasteride and weekly microneedling. Progress photos from October 2024 to January 2025 show positive changes.

The conversation is about starting a hair loss treatment using a topical solution containing RU58841, Minoxidil, and Copper Peptides. The user plans to test the product and share updates on its effectiveness.

The conversation discusses a product called Rexagain Mixprocapil, which includes topical finasteride. Users express skepticism about the product's legitimacy and caution about its use.

Breezula passed a clinical trial in August and there are questions about its availability in 2021 and potential delays due to Covid. No specific treatments were discussed.

MinoxidilMax stopped selling topical finasteride products, leaving users to seek alternatives like Morr-5 from other sources. The user expressed concern about switching products and potentially losing hair regrowth progress.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.

A user shared progress pictures after 5 months of using 1mg finasteride daily, 1ml minoxidil topically every night, and 1.5mm microneedling weekly. Responses included skepticism and congratulations.

The user experienced significant hair regrowth after 7 months using topical minoxidil once a day and 0.5mg dutasteride every other day, with noticeable results in the last two to three months. They reported no side effects and did not use dermarolling.

Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.

A user discusses a topical treatment combining Minoxidil, Betamethasone Valerate, Canrenone, Finasteride, and Dutasteride for hair loss. The treatment is RX-only and provided by a dermatologist.

Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

The user started using Hims Finasteride and Minoxidil topical in July 2023, added daily microneedling in November, and switched to chewable Finasteride and Minoxidil in January with increased microneedling frequency. They observed hair regrowth, suggesting diffuse thinning may be easier to treat.

Oral minoxidil is considered more convenient and effective for some users, with positive results reported, but concerns about side effects and availability persist. Finasteride remains a standard treatment, while some users explore combinations with other treatments like dutasteride and laser devices.

Pyrilutamide's mainstream product release date is discussed. Side effects found in studies are also questioned.

A 39-year-old has been using topical 5% minoxidil for 11 years, added microneedling, and recently started using a topical combination of minoxidil and 0.3% finasteride, noticing some hair regrowth after three months. They experienced minor side effects when switching finasteride concentrations and plan to continue the treatment, possibly adding oral finasteride or dutasteride if significant progress is seen after a year.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

The conversation discusses whether to take oral minoxidil in a split dose or a single dose at night. Users suggest that taking a single 10mg dose at night is simpler, while splitting may help minimize side effects.

A 26-year-old male shared his 3-month progress using Minoxidil and finasteride daily, microneedling weekly, and occasional vitamin D3. A commenter praised his impressive results.

A user shared their hair regrowth progress after using minoxidil 5% twice daily since January 31 and adding oral dutasteride 0.5mg and minoxidil 2mg daily two weeks ago. They also used microneedling occasionally and are seeking opinions on potential further gains.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.